COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5-11 Years Old-Non-Randomized Clinical Trial.
Agnieszka Matkowska-KocjanJoanna Owoc-LempachKamila Maria LudwikowskaFilip SzenbornNatalia MoskwaKatarzyna KurekKrzysztof KałwakLeszek SzenbornMarek UssowiczPublished in: Vaccines (2023)
The COVID-19 mRNA BNT162b2 vaccine is very well tolerated and highly immunogenic in 5-11-year-old children after HSCT. Children >2 years of age after HSCT who did not receive immunosuppressive treatment presented excellent antibody production after two doses of the vaccine, but children on immunosuppression may require a more intense vaccination schedule.